Prasinezumab for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests a new medication called prasinezumab, given through a vein (IV), to see if it can slow the progression of early-stage Parkinson's disease. It is for people who are on only one Parkinson's medication and have not yet developed motor complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh between 88 and 242 pounds and have a body mass index between 18 and 34.
- Have been diagnosed with early-stage Parkinson's disease by a doctor using standard criteria.
- Be taking only one Parkinson's medication (monotherapy) at the time of the study.
- Have no motor complications from your medication (like uncontrolled movements or wearing-off).
- Be in the early stages of Parkinson's (Hoehn and Yahr Stage 1 or 2) when off medication.
- Agree to use contraception if needed, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a drug called prasinezumab can help prevent memory and thinking problems in people with Parkinson's disease who have a specific change in their GBA gene. It looks at whether the treatment can slow down cognitive decline.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This trial tests if the blood pressure drug terazosin can help slow down Parkinson's disease. It is for people recently diagnosed (within 3 years) who are not yet on many Parkinson's medications.
This study tests an experimental treatment (LY3962681) for people with early Parkinson's. It aims to see if the treatment is safe and can slow the disease. You must have a confirmed diagnosis, be in good overall health, and have stable medication use.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.